A specially developed test rig that simulates the tilting movements of pistons at the end of strokes was used in the test.
Intrinsic factors involve the actual shape of characters and include features such as case, width, weight, stroke modulation, form groups, serifs (projecting features at the end of strokes) and slant.
The primary efficacy end point is the composite end points of stroke, systemic embolic event, myocardial infarction, and cardiovascular (CV) mortality, from randomization until the end of follow-up (day 56 post cardioversion).
When the combined end points of stroke, acute coronary syndrome, and death or cardiovascular death were studied, favorable results were also seen with dronedarone compared with placebo (P = 0.002 and P < 0.001, respectively).
The MACZ model simulates the chemical kinetics of unburned air fuel mixture from the start of compression stroke to the end of expansion stroke based on the recorded in-cylinder pressure.
The primary end point of stroke, myocardial infarction and cardiovascular death was significantly reduced by 38% (p = 0.0031), stroke rate was reduced by 45% (p = 0.0081) and there was also a significant reduction in death rate among the actively treated patients.
This higher risk was apparently independent of VKA use for the end points of stroke (ischaemic or haemorrhagic or both) (table 3).
This risk increase was apparent for the end points of stroke (ischaemic or haemorrhagic or both) whether or not a vitamin K antagonist (VKA) was used.
SBP was lower in the treatment group (143 mmHg) than the control group (155 mmHg) and the primary end point of stroke was significantly reduced by 36% (p = 0.0003), heart failure by 49% and coronary events by 27%.
